{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:00:12Z","timestamp":1781244012493,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare Epstein-Barr virus (EBV)-associated subtype of non-small cell lung cancer (NSCLC), accounting for less than 1% of all NSCLC cases. Because prospective data are scarce, no standardized perioperative strategy has been established. We report the case of a 68-year-old female never-smoker diagnosed with stage IIIC PPLELC (cT3N3M0). The patient received four cycles of neoadjuvant therapy consisting of gemcitabine plus cisplatin in combination with ivonescimab, a novel PD-1\/VEGF bispecific antibody, followed by radical surgical resection. Postoperative pathological examination revealed no residual viable tumor cells, indicating a pathological complete response (pCR). At the latest follow-up (March 2026, approximately eight months after diagnosis), no radiological evidence of recurrence or distant metastasis was observed. To our knowledge, this is the first reported case of neoadjuvant PD-1\/VEGF bispecific antibody combined with chemotherapy in locally advanced PPLELC, that achieved both pCR and R0 resection. This case suggests the potential feasibility and antitumor activity of neoadjuvant ivonescimab combined with chemotherapy in locally advanced PPLELC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1826272","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:48:46Z","timestamp":1781243326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant PD-1\/VEGF bispecific antibody combined with chemotherapy for locally advanced pulmonary lymphoepithelioma-like carcinoma achieving pathological complete response: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuanli","family":"You","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hainan Cancer Hospital","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hainan Cancer Hospital","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hainan Cancer Hospital","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hainan Cancer Hospital","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hainan Cancer Hospital","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"757085","DOI":"10.21203\/rs.3.rs-453671\/v1","article-title":"A rare subtype of non-small cell lung cancer: Report of 159 resected pathological stage I-IIIA pulmonary lymphoepithelioma-like carcinoma cases","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.01.25","article-title":"Advanced primary pulmonary lymphoepithelioma-like carcinoma: Clinical manifestations, treatment, and outcome","volume":"9","author":"Lin","year":"2017","journal-title":"J Thorac Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-sitc2023.1194","article-title":"1194 mechanism of action of ivonescimab (AK112\/SMT112): A first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects","volume":"11","author":"Zhong","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024453","article-title":"Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma","volume":"29","author":"Li","year":"2022","journal-title":"Chin J Clin Med"},{"key":"B5","article-title":"Analysis of multi-slice spiral CT imaging features and diagnostic value in patients with primary pulmonary lymphoepithelioma-like carcinoma","volume":"5","author":"Shasha","year":"2022","journal-title":"Harbin Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-022-02097-6","article-title":"Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: A population-based, multicentre, real-world study","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4103\/atm.atm_304_17","article-title":"Primary pulmonary lymphoepithelioma-like carcinoma in Singapore","volume":"13","author":"Tay","year":"2018","journal-title":"Ann Thorac Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1309\/148k-nd54-6njx-na61","article-title":"Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China","volume":"114","author":"Han","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/jcma.0000000000000363","article-title":"Computed tomography-based differentiation of primary pulmonary lymphoepithelioma-like carcinoma and small-cell lung cancer","volume":"83","author":"Lee","year":"2020","journal-title":"J Chin Med Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S241337","article-title":"Pulmonary lymphoepithelioma-like carcinoma: A mini-review","volume":"13","author":"Hu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626566","article-title":"Immune checkpoint blockade therapy may be a feasible option for primary pulmonary lymphoepithelioma-like carcinoma","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.12.014","article-title":"Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: Summary of eighty-five cases","volume":"20","author":"Qin","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240729","article-title":"The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis","volume":"15","author":"Tang","year":"2020","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1576951","article-title":"Post-hoc analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer","volume":"16","author":"Shao","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826272\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:48:50Z","timestamp":1781243330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826272\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1826272"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1826272","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1826272"}}